CTOs on the Move


 
StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery primarily in the United States. Its lead therapeutic product candidate, HuCNS-SC cells (purified human neural stem cells), is in development as a potential treatment for a range of central nervous system disorders. The company has conducted a Phase I clinical trial in Pelizaeus-Merzbacher disease, a fatal myelination disorder in children. It is also conducting a Phase I/II clinical trial in chronic spinal cord injury; and has initiated a Phase I/II clinical trial in dry ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

AZTherapies, Inc.

AZTherapies, Inc. is a private, late-stage clinical biopharmaceutical company developing treatments for devastating neurological conditions.

Altheus Therapeutics

Altheus Therapeutics is a Oklahoma City, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vono Medical Supplies

Vono Medical Supplies is a Springfield, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PriceSpective

PriceSpective is a Blue Bell, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nanoscope Therapeutics

Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope`s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells.